Primary sclerosing cholangitis: epidemiology, risk factors, pathophysiology, clinical features, diagnosis, and management
Year: 2026
Type: article
Abstract: Primary sclerosing cholangitis (PSC) is a rare cholangiopathy characterized by multifocal inflammation and fibrostenotic remodeling of the bile ducts, cholestasis, and increased risks of cholangiocarcinoma and colorectal cancer. No pharmacological therapy has yet improved transplant-free survival. Clinical care therefore depends on accurate phenotyping, surveillance, treatment of biliary and intestinal complications, and timely liver transplantation. Population-based and clinical studies define the epidemiology, risk factors, presentation, diagnosis, and management of PSC. Studies of human biospecimens, including microbiome and metabolomic analyses, describe biological changes associated with the disease, whereas organoid and animal models are used to investigate potential mechanisms. The available evidence links genetic susceptibility and PSC-associated inflammatory bowel disease to cholangiocyte injury, immune activation, disturbed bile acid homeostasis, and microbial alterations. At the bile duct interface, cholangiocyte senescence and barrier dysfunction may interact with microbial exposure and immune-cell recruitment to promote periductal fibrosis. PSC is therefore more plausibly viewed as a multicellular process than as the consequence of a single microbial, immune, or bile acid pathway. Whether dysbiosis and altered bile acid profiles contribute to disease development or instead reflect established PSC remains unresolved. Concomitant inflammatory bowel disease, medication use, biliary obstruction, and previous biliary interventions further complicate causal inference. Longitudinal human studies may distinguish early drivers from secondary changes. Mechanistic findings should ultimately improve patient phenotyping, surveillance, endoscopic management, and selection for targeted trials. Such trials will require biologically informed designs and endpoints that capture durable clinical benefit.
Source: Molecular Biomedicine
Institutions: Shanghai Jiao Tong University, Renji Hospital
Language: English
Topic: Liver Diseases and Immunity
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,590
OpenAlex ID: W7237337033
